Heterogeneity of advanced prostate cancer: clinical implications of genomics

This report is based on a session held during the 13th Annual Meeting of the British Uro-oncology Group (BUG) in London in September 2016. The session discussed the clinical implications of genomics in the management of advanced prostate cancer, in the context of the potential use of biomarkers to predict outcomes to treatment and the future of biomarker-driven trials.

Read the full article

Add yours ↓
Web design and marketing agency Leamington Spa